文献速递肾癌与肾肿瘤

减瘤性肾切除术在肉瘤样肾细胞癌中的作用:29年单中心经验

The Role of Cytoreductive Nephrectomy for Sarcomatoid Renal Cell Carcinoma: A 29-Year Institutional Experience.
PubMed 文献 · Urology · 2019-11-11

本研究回顾性分析了1989至2018年间接受减瘤性肾切除术的562例转移性肾细胞癌患者,其中192例为肉瘤样去分化(sRCC)。sRCC患者中位随访14个月,2年和5年总生存率分别为34.1%和14.8%;肝、肺、腹膜后淋巴结转移及非透明细胞组织学与更差的总生存相关。

要点

  • sRCC患者减瘤性肾切除术后2年OS为34.1%,5年OS为14.8%。
  • 肝、肺、腹膜后淋巴结转移及非透明细胞组织学与更差OS独立相关。
  • 单发转移、无肝肺转移、透明细胞组织学及淋巴结阴性者可能更多获益。

核心结论

  • sRCC与非sRCC患者减瘤性肾切除术后总生存随时间改善。
  • sRCC患者中,单发转移且无肝肺转移、透明细胞组织学及淋巴结阴性者预后更好。

研究设计与样本

  • 回顾性单中心研究,纳入1989至2018年接受减瘤性肾切除术的562例转移性肾细胞癌患者,其中sRCC 192例。

主要发现

  • sRCC患者中位年龄59岁,常见转移部位为肺(n=115)、腹膜后淋巴结(n=63)和中轴骨(n=43)。
  • sRCC患者中位随访14个月,估计2年OS为34.1%,5年OS为14.8%。

临床怎么用

  • 对于sRCC患者,减瘤性肾切除术的获益需结合转移部位、组织学亚型及淋巴结状态个体化评估。
  • 单发转移、无肝肺转移、透明细胞组织学及淋巴结阴性的sRCC患者可能从减瘤性肾切除术中更多获益。

局限性

  • 回顾性单中心设计,样本来自1989至2018年,治疗模式可能随时间变化。
  • 中位随访仅14个月,长期生存数据受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess which patients respond best following cytoreductive nephrectomy for renal cell carcinoma (RCC) with sarcomatoid dedifferentiation (sRCC) and whether outcomes are improving over time. METHODS: We identified 562 patients with metastatic RCC treated between 1989 and 2018 with cytoreductive nephrectomy. We reviewed baseline clinical and pathologic characteristics, including the presence of sRCC, and metastatic sites at time of nephrectomy. The primary study endpoint was overall survival (OS). Univariate and multivariate Cox-regression analyses were used to identify significant predictors of OS. RESULTS: The study cohort had 192 sRCC patients, with a median age of 59 years. Frequently involved metastatic locations were lung (n = 115), retroperitoneal nodes (n = 63), and axial skeleton (n = 43). Lung metastasis were more prevalent in clear cell histology (P = .0017) whereas nodal involvement was associated with nonclear cell subtypes (P = .0064). Median follow-up was 14 months. Estimated 2- and 5-year OS were 34.1% and 14.8%, respectively. On multivariate analysis, metastases to the liver (HR = 1.64; 95% CI 1.02-2.63; P = .04), lung (HR = 1.50; 95% CI 1.05-2.14; P = .03), retroperitoneal nodes (HR = 1.52; 95% CI 1.03-2.25; P = 0.04) and nonclear cell histology (HR = 1.61; 95% CI 1.10-2.35; P = .01) were associated with worse OS in the sRCC cohort. CONCLUSION: OS after cytoreductive nephrectomy for sRCC and non-sRCC is improving over time. In patients with sRCC, presentations with unifocal metastasis not involving the liver or lung, clear cell histology and node negative disease have better outcomes following cytoreductive nephrectomy and may yield greater benefit from the procedure.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Silagy AW, Mano R, Blum KA, et al. The Role of Cytoreductive Nephrectomy for Sarcomatoid Renal Cell Carcinoma: A 29-Year Institutional Experience. Urology. 2019. PMID: 31726184. doi:10.1016/j.urology.2019.08.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。